These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 39068560)

  • 1. Immune-Related Adverse Events due to Concomitant Use of Immune Checkpoint Inhibitors and Chinese Herbal Medicines: A Study Based on a Japanese Adverse Event Database.
    Koshiishi T; Nishioka N; Yoshimoto K
    Asian Pac J Cancer Prev; 2024 Jul; 25(7):2291-2295. PubMed ID: 39068560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cross-Cancer Type Evaluation of Potential Interstitial Lung Disease Complications of Immune Checkpoint Inhibitors Using JADER.
    Koga K; Tasaka Y; Nawa H
    Biol Pharm Bull; 2024; 47(7):1296-1300. PubMed ID: 39010215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Colitis following the use of immune checkpoint inhibitors: A real-world analysis of spontaneous reports submitted to the FDA adverse event reporting system.
    Hu Y; Gong J; Zhang L; Li X; Li X; Zhao B; Hai X
    Int Immunopharmacol; 2020 Jul; 84():106601. PubMed ID: 32422528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse events associated with immune checkpoint inhibitors in non-small cell lung cancer: a safety analysis of clinical trials and FDA pharmacovigilance system.
    Liang X; Xiao H; Li H; Chen X; Li Y
    Front Immunol; 2024; 15():1396752. PubMed ID: 38745663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune checkpoint inhibitors-related myocarditis in patients with cancer: an analysis of international spontaneous reporting systems.
    Ma R; Wang Q; Meng D; Li K; Zhang Y
    BMC Cancer; 2021 Jan; 21(1):38. PubMed ID: 33413213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune-related adverse events associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system.
    Chen C; Wu B; Zhang C; Xu T
    Int Immunopharmacol; 2021 Jun; 95():107498. PubMed ID: 33725634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Effect of Concomitant Usage of Analgesics on Immune Checkpoint Inhibitor-related Interstitial Lung Disease.
    Manabe T; Iwayama K; Chuma M; Tasaki Y; Matsumoto S
    In Vivo; 2023; 37(3):1260-1265. PubMed ID: 37103090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune-related adverse events and immune checkpoint inhibitor tolerance on rechallenge in patients with irAEs: a single-center experience.
    Bhatlapenumarthi V; Patwari A; Harb AJ
    J Cancer Res Clin Oncol; 2021 Sep; 147(9):2789-2800. PubMed ID: 33774736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune checkpoint inhibitor-associated interstitial lung diseases correlate with better prognosis in patients with advanced non-small-cell lung cancer.
    Sugano T; Seike M; Saito Y; Kashiwada T; Terasaki Y; Takano N; Hisakane K; Takahashi S; Tanaka T; Takeuchi S; Miyanaga A; Minegishi Y; Noro R; Kubota K; Gemma A
    Thorac Cancer; 2020 Apr; 11(4):1052-1060. PubMed ID: 32096610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Haemophagocytic lymphohistiocytosis in patients treated with immune checkpoint inhibitors: analysis of WHO global database of individual case safety reports.
    Noseda R; Bertoli R; Müller L; Ceschi A
    J Immunother Cancer; 2019 May; 7(1):117. PubMed ID: 31046841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune-related adverse events of immune checkpoint inhibitors combined with angiogenesis inhibitors: A real-world pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database (2014-2022).
    Ren X; Wang H; Deng L; Wang W; Wang Y
    Int Immunopharmacol; 2024 Jul; 136():112301. PubMed ID: 38838553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discontinuation due to immune-related adverse events is a possible predictive factor for immune checkpoint inhibitors in patients with non-small cell lung cancer.
    Komiya K; Nakamura T; Abe T; Ogusu S; Nakashima C; Takahashi K; Kimura S; Sueoka-Aragane N
    Thorac Cancer; 2019 Sep; 10(9):1798-1804. PubMed ID: 31328416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of immune-related adverse events caused by immune checkpoint inhibitors using the Japanese Adverse Drug Event Report database.
    Hasegawa S; Ikesue H; Nakao S; Shimada K; Mukai R; Tanaka M; Matsumoto K; Inoue M; Satake R; Yoshida Y; Goto F; Hashida T; Nakamura M
    Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1279-1294. PubMed ID: 32869941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of severe immune-related adverse events requiring hospital admission in patients on immune checkpoint inhibitors: study of a population level insurance claims database from the USA.
    Kalinich M; Murphy W; Wongvibulsin S; Pahalyants V; Yu KH; Lu C; Wang F; Zubiri L; Naranbhai V; Gusev A; Kwatra SG; Reynolds KL; Semenov YR
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33789879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System.
    Raschi E; Mazzarella A; Antonazzo IC; Bendinelli N; Forcesi E; Tuccori M; Moretti U; Poluzzi E; De Ponti F
    Target Oncol; 2019 Apr; 14(2):205-221. PubMed ID: 30927173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-World Clinical and Economic Outcomes in Selected Immune-Related Adverse Events Among Patients with Cancer Receiving Immune Checkpoint Inhibitors.
    Zheng Y; Kim R; Yu T; Gayle JA; Wassel CL; Dreyfus J; Phatak H; George S
    Oncologist; 2021 Nov; 26(11):e2002-e2012. PubMed ID: 34327774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States.
    Yang F; Shay C; Abousaud M; Tang C; Li Y; Qin Z; Saba NF; Teng Y
    J Exp Clin Cancer Res; 2023 Jan; 42(1):4. PubMed ID: 36600271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone fracture as a novel immune-related adverse event with immune checkpoint inhibitors: Case series and large-scale pharmacovigilance analysis.
    Filippini DM; Gatti M; Di Martino V; Cavalieri S; Fusaroli M; Ardizzoni A; Raschi E; Licitra L
    Int J Cancer; 2021 Aug; 149(3):675-683. PubMed ID: 33844854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors of immune checkpoint inhibitor-related interstitial lung disease in patients with lung cancer: a single-institution retrospective study.
    Okada N; Matsuoka R; Sakurada T; Goda M; Chuma M; Yagi K; Zamami Y; Nishioka Y; Ishizawa K
    Sci Rep; 2020 Aug; 10(1):13773. PubMed ID: 32792640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.
    Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhuang Y; He J
    J Immunother Cancer; 2019 Nov; 7(1):286. PubMed ID: 31694698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.